Related Experiment Videos
Targeted treatments for cirrhosis
Jonathan A Fallowfield1, John P Iredale
1Liver Research Group, Division of Infection, Inflammation and Repair, Southampton General Hospital, Mailpoint 811, D Level, Southampton, SO16 6YD, UK. jonfalluk@yahoo.co.uk
Expert Opinion on Therapeutic Targets
|October 8, 2004
Summary
Hepatic fibrosis leads to cirrhosis and significant health burdens. Eliminating hepatic stellate cells is key to potentially reversing liver fibrosis and cirrhosis.
Area of Science:
- Hepatology
- Fibrosis Research
- Cellular Biology
Background:
- Hepatic scarring (fibrosis) progresses to cirrhosis, disrupting liver architecture and causing severe complications.
- Cirrhosis presents a substantial global healthcare challenge, despite advances in transplantation and antiviral therapies.
- Current treatments for liver disease often fail to address the underlying fibrotic process, necessitating new therapeutic strategies.
Purpose of the Study:
- To review recent scientific advances in understanding liver fibrosis.
- To highlight emerging therapeutic interventions targeting the fibrotic process.
- To emphasize the potential reversibility of advanced fibrosis and cirrhosis.
Main Methods:
- Review of accumulating clinical and laboratory data.
- Identification of pivotal effector cells in hepatic fibrogenesis.
- Analysis of mechanisms underlying fibrosis reversibility.
Main Results:
- Hepatic stellate cells are identified as the key cells orchestrating liver fibrosis.
- Evidence suggests that even advanced fibrosis and cirrhosis may be reversible.
- Reversibility of fibrosis appears to be linked to the elimination of hepatic stellate cells.
Conclusions:
- The development of antifibrotic therapies is urgently needed.
- A mechanistic and evidence-based approach is required for developing new treatments.
- Targeting hepatic stellate cell elimination offers a promising therapeutic strategy for liver fibrosis.